Bluejay Diagnostics, Inc.
BJDXHealthcareNASDAQMedical Devices · Last scanned Sep 4, 2026
Scan Results
Daily timeframe1 of 4 indicators bullish as of Sep 3
Headquartered within the healthcare sector, Bluejay Diagnostics, Inc. focuses on Medical Devices services and products. Bluejay Diagnostics, Inc. operates as a medical diagnostics company. With a market capitalization of $878K, it sits in micro-cap territory. It offers Symphony technology platform which consists of an analyzer and single-use protein detection cartridges that are designed to provide measurements of key diagnostic biomarkers found in blood; and Symphony analyzer used to orchestrate sample processing of whole blood, plasma, serum, etc., biomarker isolation, and immunoassay preparation using non-contact centrifugal force.
Market Cap
$878,369
Beta
0.89
P/E (TTM)
—
P/E (Fwd)
-2.65
EPS (TTM)
$-2.27
EPS (Fwd)
$-0.32
ROE
-98.9%
ROA
-51.1%
Cash
$9.6M
Total Debt
$80,670
Free CF
-$3.5M
52W Change
-85.0%
Annual Financials
Cash vs Debt
Where BJDX stands vs its 150-day and 200-day moving averages
As of the September 3, 2026 close, BJDX finished 58.74% below its 150-day moving average ($2.06) and 66.00% below its 200-day moving average ($2.50). This snapshot is end-of-day data shown with a five-trading-day delay on the free plan; Premium members see readings from the latest close.
Is BJDX overbought or oversold?
At the September 3, 2026 close, BJDX's RSI(14) was 12.2, in oversold territory (below 30). The MACD histogram was positive, so short-term momentum leaned bullish at that close. These readings are historical, refresh daily after market close, and are not investment advice.
With $9.6M in cash and $81K in debt, BJDX maintains more liquidity than leverage. This favorable balance sheet position can be an asset when capital markets become less accommodating. Free cash flow is running at -$3.5M, which bears watching. Negative free cash flow can be acceptable during heavy investment periods but needs to improve over time. ROE of -98.9% points to negative capital efficiency, indicating how much profit the company produces per dollar of shareholder equity. Revenue has pulled back from $249K (2022) to $0 (2025), a 100% decline worth watching.
With cash comfortably exceeding debt, BJDX has financial flexibility that may help navigate uncertain periods. The company is burning cash at the operating level, which is not unusual for growth-phase companies but adds risk if it persists. Understanding these risk dimensions helps frame what to watch going forward as conditions evolve for Bluejay Diagnostics, Inc. and its sector.